Login to Your Account

Balancing innovation and affordability

Glaxosmithkline plc has had a rough couple of years in China. But the big pharma is seeking now to emerge from the dust of a scandal that forced it to pay a $3 billion fine for giving bribes to boost drug sales and led to suspended prison sentences for five executives.

more »


Partners in Focus